诺华以120亿美元收购罕见病生物技术公司Avidity,创公司十多年最大收购案,溢价46%。Avidity三种在研药物预计2030年前上市,峰值年销售额可达数十亿美元,将助力诺华应对专利悬崖。此次交易将诺华2024-2029年复合年增长率从5%提升至6%。瑞士制药巨头诺华同意以120亿美元收购专注罕见病的生物技术公司Avidity Biosciences,这是该公司十多年来规模最大的一笔收购。后者...
Source Link诺华以120亿美元收购罕见病生物技术公司Avidity,创公司十多年最大收购案,溢价46%。Avidity三种在研药物预计2030年前上市,峰值年销售额可达数十亿美元,将助力诺华应对专利悬崖。此次交易将诺华2024-2029年复合年增长率从5%提升至6%。瑞士制药巨头诺华同意以120亿美元收购专注罕见病的生物技术公司Avidity Biosciences,这是该公司十多年来规模最大的一笔收购。后者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.